Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1238 views | HTML 1971 views | ?
Alina D. Nikotina1, Lidia Koludarova1, Elena Y. Komarova1, Elena R. Mikhaylova1, Nikolay D. Aksenov1, Roman Suezov1,3, Viktor G. Kartzev2, Boris A. Margulis1 and Irina V. Guzhova1
1Laboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg 194064, Russia
2InterBioscreen, Chernogolovka 142432, Russia
3Saint Petersburg Technical University, St. Petersburg 190013, Russia
Irina V. Guzhova, email: [email protected]
Keywords: heat shock factor 1 (HSF1); Hsp70; anticancer drugs; combined antitumor therapy
Received: February 19, 2018 Accepted: May 19, 2018 Published: June 05, 2018
Combinational anticancer therapy demonstrates increased efficiency, as it targets different cell-survival mechanisms and allows the decrease of drug dosages that are often toxic to normal cells. Inhibitors of the heat shock response (HSR) are known to reduce the efficiency of proteostasis mechanisms in many cancerous cells, and therefore, may be employed as anti-tumor drug complements. However, the application of HSR inhibitors is limited by their cytotoxicity, and we suggested that milder inhibitors may be employed to sensitize cancer cells to a certain drug.
We used a heat-shock element-luciferase reporter system and discovered a compound, CL-43, that inhibited the levels of heat shock proteins 40, 70 (Hsp70), and 90 kDa in HCT-116 cells and was not toxic for cells of several lines, including normal human fibroblasts. Consequently, CL-43 was found to reduce colony formation and motility of HCT-116 in the appropriate assays suggesting its possible application in the exploration of biology of metastasizing tumors. Importantly, CL-43 elevated the growth-inhibitory and cytotoxic activity of etoposide, cisplatin, and doxorubicin suggesting that the pro-drug has broad prospect for application in a variety of anti-tumor therapy schedules.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.